Lantheus以350万美元购买生命分子成像, 目标是阿尔茨海默氏的诊断增强。 Lantheus buys Life Molecular Imaging for $350M, targeting Alzheimer's diagnostics boost.

Lantheus控股公司以3.5亿美元购买生命分子成像有限公司,今后可能再支付4亿美元。 Lantheus Holdings acquired Life Molecular Imaging Ltd for $350 million, with potential for an additional $400 million in future payments. 这项交易提高了Lantheus在阿尔茨海默氏病诊断方面的能力,特别是与Neuraceq的诊断能力,Neuraceq是用于检测乙酰胺斑块的PET成像剂。 This deal enhances Lantheus' capabilities in Alzheimer's disease diagnostics, particularly with Neuraceq, a PET imaging agent for detecting beta-amyloid plaques. 收购的目的是在一年内提升Lantheus的EPS,并加强其放射制药投资组合和研发。 The acquisition aims to boost Lantheus' EPS within a year and strengthen its radiopharmaceutical portfolio and R&D.